Proton Reirradiation: Expert Recommendations for Reducing Toxicities and Offering New Chances of Cure in Patients With Challenging Recurrence Malignancies.
05/07/2020
/
Publications
/
Toxicity
Reirradiation
IMPT
Published in Seminar Radiation Oncology, this review article evaluated clinical data up-to-date on proton reirradiation for local and regional recurrence. As...
Toxicity and Survival After IMPT Versus Passive Scattering PT for NSCLC.
10/10/2020
/
Publications
/
Toxicity
IMPT
This MD Anderson study compared toxicity profiles and clinical outcomes after IMPT versus PSPT for 139 patients with locally advanced NSCLC. Compared to the...
Proton Therapy in NSCLC
11/11/2018
/
Publications
/
IMPT
Immunotherapy
A review on PBT for NSCLC. The review pointed out that despite early results suggesting improvements or at least comparable outcomes, the most recent randomized...
Patterns of Local-Regional Failure after IMRT or Passive Scattering PT with Concurrent Chemotherapy for NSCLC.
08/08/2018
/
Publications
/
IMPT
Published in the Red Journal, this retrospective analysis by MD Anderson group reviewed 212 patients treated with IMRT and PT, most (152 [72%]) had no failure...
Advanced radiation techniques for locally advanced NSCLC: IMRT and proton therapy.
08/08/2018
/
Publications
/
IMPT
IMRT
This review article examined clinical outcomes data of IMRT and PBT for locally advanced NSCLC. This review pointed out that PBT is not considered the standard...
Reirradiation for locoregionally recurrent non-small cell lung cancer.
08/08/2018
/
Publications
/
Reirradiation
IMPT
Survival
In the context of definitive retreatment, increasing reRT dose can potentially improve OS and offer a chance of cure, particularly in patients with limited loco...
Clinical outcomes of intensity modulated proton therapy and concurrent chemotherapy in esophageal carcinoma (EC).
11/06/2017
/
Publications
/
IMPT
Chemotherapy
Toxicity
19 patients with EC treated with IMPT concurrently with chemotherapy. Clinical complete response was achieved in 84%.
The most common grade 3 acute toxicities...
High-dose Intensity-modulated proton therapy versus Standard-dose Intensity-modulated RadIation therapy for esophageal squamous cell carcinoma (HI-SIRI): study protocol for a randomized controlled clinical trial.
15/11/2022
/
Publications
/
IMPT
IMRT
This is a study protocol details a randomized trial taking place in Thailand with multiple centers comparing IMPT and IMRT for stage II–IVA squamous thoracic...
Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung Cancer.
15/11/2022
/
Publications
/
IMPT
IMRT
163 consecutively treated patients with biopsy-proven, stage III NSCLC who received IMPT (n = 35, 21%) or IMRT (n = 128, 79%) were analyzed in this study...
Proton and photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and adjuvant immune therapy.
28/03/2024
/
Publications
/
IMPT
IMRT
Toxicity
This study reported the incidence of lymphopenia in 271 stage III NSCLC patients treated with IMPT (n=71) vs IMRT (n=200) and concurrent chemotherapy. The...
Cookies policy
If you continue browsing this website, you agree to the use of cookies in order to provide you with services and offers tailored to your own interests.
Manage your cookie preferences
Respect for your privacy is still a priority for us at IBA.
Functional cookies ensure that the website runs smoothly. They cannot be turned off. By setting your preferences, you can turn the use of these cookies on and off on our website, although these settings will only be valid on the device you are currently using.